<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03788434</url>
  </required_header>
  <id_info>
    <org_study_id>CONSORTIUM (VE303-002)</org_study_id>
    <nct_id>NCT03788434</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection</brief_title>
  <acronym>CONSORTIUM</acronym>
  <official_title>CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedanta Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedanta Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of VE303 for participants with primary C.&#xD;
      difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C.&#xD;
      difficile infections (rCDI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CONSORTIUM is a randomized, double-blind phase 2 study to evaluate safety, tolerability,&#xD;
      PK/PD, and efficacy of VE303 in prevention of subsequent CDI-associated diarrhea compared&#xD;
      with placebo following completion of at least 1 successful course of standard-of-care (SOC)&#xD;
      antibiotics. VE303 or placebo capsules will be taken orally for 14 days after completion of a&#xD;
      course of standard of care antibiotics. The proportion of subjects experiencing a confirmed&#xD;
      CDI recurrence, within 8 weeks after the first dose of study treatment, will be compared&#xD;
      across the study arms to understand the effectiveness of VE303 in preventing rCDI.&#xD;
&#xD;
      The study will enroll approximately 60 to 80 subjects with a prior history of CDI diarrhea or&#xD;
      first occurrence of CDI diarrhea with a higher risk for recurrence. Subjects must also have a&#xD;
      positive C. difficile stool sample and have responded to standard of care (SOC) antibiotic&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2019</start_date>
  <completion_date type="Actual">September 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 2, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This Phase 2 study will help determine how safe and effective the study drug, VE303, is at preventing subsequent Clostridium difficile Infection (CDI)-associated diarrhea compared with placebo, following completion of at least 1 successful course of standard-of-care (SOC) antibiotics for subjects with primary C. difficile infection (pCDI) at high risk for recurrence or subjects with recurrent CDI.&#xD;
Patients in the study will be randomized into 3 arms in a 1:1:1 ratio of high dose VE303, low dose VE303, and placebo.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>To reduce potential bias and increase study data integrity, study participants, care providers, site investigators, and study outcomes assessors will all be masked to study treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Selection of Phase 3 dose for VE303</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary objective is to determine the recommended VE303 Phase 3 dose regimen based on safety and efficacy, as indicated by the C difficile infection (CDI) recurrence rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize VE303 colonization</measure>
    <time_frame>24 weeks</time_frame>
    <description>Secondary objective is to characterize VE303 colonization in the fecal microbiome after 14 days of treatment with VE303.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Changes in the Fecal Microbiome</measure>
    <time_frame>24 weeks</time_frame>
    <description>Secondary objective is to characterize changes in the fecal microbiome after 14 days of treatment with VE303.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CDI recurrence week 8</measure>
    <time_frame>8 weeks after first study dose</time_frame>
    <description>Proportion of subjects with CDI recurrence before or at Week 8 (i.e., 8 weeks after the first dose of study treatment).</description>
  </other_outcome>
  <other_outcome>
    <measure>CDI recurrence week 4</measure>
    <time_frame>4 weeks after first study dose</time_frame>
    <description>Proportion of subjects without CDI recurrence before or at Week 4 (i.e., 4 weeks after the first dose of study treatment)</description>
  </other_outcome>
  <other_outcome>
    <measure>CDI recurrence week 12</measure>
    <time_frame>12 weeks after first study dose</time_frame>
    <description>Proportion of subjects without CDI recurrence before or at Week 12 (i.e., 12 weeks after the first dose of study treatment)</description>
  </other_outcome>
  <other_outcome>
    <measure>CDI recurrence week 24</measure>
    <time_frame>24 weeks after first study dose</time_frame>
    <description>Proportion of subjects without CDI recurrence before or at Week 24 (i.e., 24 weeks after the first dose of study treatment).</description>
  </other_outcome>
  <other_outcome>
    <measure>Microbiota diversity</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes in fecal taxonomic composition after 14 days of blinded treatment with VE303.</description>
  </other_outcome>
  <other_outcome>
    <measure>Taxonomic Composition</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes in fecal taxonomic composition after 14 days of blinded treatment with VE303.</description>
  </other_outcome>
  <other_outcome>
    <measure>Metabolomic profile</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes in the fecal metabolomic profile, including short chain fatty acids and bile acids after 14 days of blinded treatment with VE303.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Clostridium Difficile Infection Recurrence</condition>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Clostridium Difficile</condition>
  <condition>CDI</condition>
  <arm_group>
    <arm_group_label>VE303 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects assigned the the high dose VE303 arm will take 10 capsules containing VE303 per day for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VE303 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects assigned to the low dose VE303 arm will take 2 capsules containing VE303 per day for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study subjects assigned to the placebo dose arm will take placebo capsules each day for 14 days. The capsules will not contain any VE303.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VE303</intervention_name>
    <description>VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under GMP conditions.</description>
    <arm_group_label>VE303 High Dose</arm_group_label>
    <arm_group_label>VE303 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules contain micro-crystalline cellulose. They are visually identical to VE303 capsules. They will be taken by mouth for 14 days. Placebo capsules will not contain any VE303 Drug Product.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Partial Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide written informed consent&#xD;
&#xD;
          2. Subjects with a qualifying CDI episode who have a prior history of CDI diarrhea or&#xD;
             first occurrence of CDI diarrhea with a higher risk for recurrence (≥ 65 years of age)&#xD;
&#xD;
          3. CDI symptoms must have started within 30 days (inclusive) prior to the day of&#xD;
             randomization&#xD;
&#xD;
          4. The diarrhea is considered unlikely to have another etiology.&#xD;
&#xD;
          5. Complete an Investigator's choice SOC antibiotic regimen of a minimum of 10 days and&#xD;
             up to 21 days of total duration&#xD;
&#xD;
          6. Have a positive C. difficile stool&#xD;
&#xD;
          7. Recovered from any complications of severe or fulminant CDI and clinically stable by&#xD;
             the time of randomization.&#xD;
&#xD;
        Partial Exclusion Criteria:&#xD;
&#xD;
          1. History of diarrhea (defined as 3 or more loose stools per day lasting for at least 4&#xD;
             weeks) that is not related to C. difficile infection within the 3 months prior to&#xD;
             randomization.&#xD;
&#xD;
          2. Known or suspected toxic megacolon and/or known small bowel ileus at the time of&#xD;
             randomization.&#xD;
&#xD;
          3. Contraindication to oral/enteral therapy (e.g., severe reflux, severe nausea/vomiting,&#xD;
             or ileus).&#xD;
&#xD;
          4. Prior administration of genetically modified investigational live&#xD;
             bacterial/fungal/bacteriophage/viral isolates for CDI-associated diarrhea&#xD;
&#xD;
          5. History of administration of fecally-derived investigational live biotherapeutic&#xD;
             products, or fecally-derived live bacterial isolates for CDI-associated diarrhea&#xD;
             including fecal microbiota transplantation (FMT) within the last 6 months.&#xD;
&#xD;
          6. Use of drugs that alter gut motility&#xD;
&#xD;
          7. History of acute leukemia or hematopoietic stem cell transplantation or&#xD;
             myelosuppressive chemotherapy within 2 months prior to randomization.&#xD;
&#xD;
          8. Subjects with compromised immune system&#xD;
&#xD;
          9. Major gastrointestinal surgery (e.g., significant bowel resection or diversion) within&#xD;
             3 months prior to randomization or any history of total colectomy or bariatric surgery&#xD;
             that disrupts the gastrointestinal lumen.&#xD;
&#xD;
         10. History of confirmed celiac disease, inflammatory bowel disease, short gut,&#xD;
             gastrointestinal tract fistulas, or ischemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phoenix Clinical, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Clinical Studies Unit</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEA Baptist Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Research Institute</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Center of Connecticut, LLC</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guardian Angel Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Health System Research Insitute</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covenant HealthCare</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Gastonia</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Institute of Clinical Research Inc</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TruCare Internal Medicine and Infectious Diseases</name>
      <address>
        <city>DuBois</city>
        <state>Pennsylvania</state>
        <zip>15801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research, LLC</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research-Be Well MD</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Centers for Infectious Disease Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinrx Research Joseph INC</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Associates of Central Virginia Infectious Disease</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Infectious Disease Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research-Spokane Gastroenterology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre - Microbial Health Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARe Clinic</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <zip>T4N6V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viable Clinical Research</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1P2T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Q&amp;T Research Chicoutimi</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H7Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Québec-Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8Z3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>December 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2018</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium Difficile Infection Recurrence</keyword>
  <keyword>Clostridium Difficile Infection</keyword>
  <keyword>Clostridium Difficile</keyword>
  <keyword>VE303</keyword>
  <keyword>Consortium</keyword>
  <keyword>Vedanta</keyword>
  <keyword>CDI</keyword>
  <keyword>C. Diff</keyword>
  <keyword>CDiff</keyword>
  <keyword>Clostridiodes Difficile Infection</keyword>
  <keyword>Clostridiodes Difficile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

